Cyxone AB (publ) decided to appoint Kjell Stenberg as new CEO with immediate effect. Kjell replaces Carl-Magnus Högerkorp, who will ensure a smooth transition. Kjell was the CEO of Cyxone from when the company was founded in 2015 until 2019.

He has thus good knowledge of Cyxone's projects, which facilitates a seamless change of management. Kjell holds a PhD in medical science, has held management positions in AstraZeneca R&D including project inlicensing from biotech. Since 2001 he has worked in biotech and with corporate financing in Europe and North America.